Huabo Biopharmaceutical

Huabo Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, serving as the primary research and development subsidiary of Lepu Biopharma. The company focuses on the discovery and development of innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) for oncology and immunotherapy. Huabo Biopharmaceutical operates a comprehensive platform that spans from early-stage drug discovery to clinical development, with a robust pipeline targeting well-validated pathways such as PD-1/PD-L1, HER2, and EGFR. Its lead programs are integrated into Lepu Biopharma's broader commercialization strategy, aiming to provide high-quality, affordable biopharmaceuticals to patients globally.